BioXcel Execs Face Investor Suit Over Alzheimer's Drug Probe

By Sydney Price · January 3, 2024, 5:47 PM EST

Top brass at artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. have been hit with a shareholder derivative suit alleging they took too long to disclose a U.S. Food and Drug Administration...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Vomvolakis v. Mehta et al

Case Number

Court

Connecticut

Nature of Suit

Stockholders Suits

Date Filed

January 02, 2024

Recent Articles By Sydney

November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
October 29, 2024
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies
October 17, 2024
Acadia Hid Wrongful Detainment Of Patients, Investor Claims
September 25, 2024
Feds Urge Judge Not To Ax Novel Insider Trading Conviction
September 24, 2024
Philips Must Face Investor Suit Over FDA Compliance Issues
July 18, 2024
Ocugen Execs Hit With Derivative Suit Over Shoddy Controls
July 15, 2024
Walgreens Investor Sues Over Challenged Pharmacy Division
July 10, 2024
Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud